177 related articles for article (PubMed ID: 3681368)
21. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study.
Lindahl LM; Fenger-Grøn M; Iversen L
Br J Dermatol; 2014 Mar; 170(3):699-704. PubMed ID: 24024659
[TBL] [Abstract][Full Text] [Related]
22. Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay.
Vonderheid EC; Dellatorre DL; Van Scott EJ
Arch Dermatol; 1981 Sep; 117(9):586-9. PubMed ID: 6457569
[TBL] [Abstract][Full Text] [Related]
23. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation).
Ysebaert L; Truc G; Dalac S; Lambert D; Petrella T; Barillot I; Naudy S; Horiot JC; Maingon P
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1128-34. PubMed ID: 15001254
[TBL] [Abstract][Full Text] [Related]
24. Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard.
Lee LA; Fritz KA; Golitz L; Fritz TJ; Weston WL
J Am Acad Dermatol; 1982 Nov; 7(5):590-8. PubMed ID: 7142467
[TBL] [Abstract][Full Text] [Related]
25. Electron-beam therapy for mycosis fungoides: the Stanford University experience.
Hoppe RT; Cox RS; Fuks Z; Price NM; Bagshaw MA; Farber EM
Cancer Treat Rep; 1979 Apr; 63(4):691-700. PubMed ID: 109207
[TBL] [Abstract][Full Text] [Related]
26. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance.
Van Scott EJ; Kalmanson JD
Cancer; 1973 Jul; 32(1):18-30. PubMed ID: 4577503
[No Abstract] [Full Text] [Related]
27. Remissions of mycosis fungoides induced by nitrogen mustard (HN2). Topical treatment and hydration of tumours and plaques with HN2. Topical desensitization to HN2. A clinical and histopathological controlled study.
Volden G; Larsen TE
Dermatologica; 1978; 156(3):129-41. PubMed ID: 342293
[TBL] [Abstract][Full Text] [Related]
28. Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up.
Hallahan DE; Griem ML; Griem SF; Medenica M; Soltani K; Lorincz AL; Baron JM
J Clin Oncol; 1988 Jul; 6(7):1177-83. PubMed ID: 3392562
[TBL] [Abstract][Full Text] [Related]
29. Topical corticosteroids for mycosis fungoides. Experience in 79 patients.
Zackheim HS; Kashani-Sabet M; Amin S
Arch Dermatol; 1998 Aug; 134(8):949-54. PubMed ID: 9722724
[TBL] [Abstract][Full Text] [Related]
30. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
Querfeld C; Geskin LJ; Kim EJ; Scarisbrick JJ; Quaglino P; Papadavid E; Angello JT; Ortiz-Romero PL
J Invest Dermatol; 2021 Jun; 141(6):1601-1604.e2. PubMed ID: 33347924
[No Abstract] [Full Text] [Related]
31. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands.
Hernández Z; Peñate Y; Hernández-Machín B; Pérez-Méndez L; Suárez-Hernández J; Hernández J; Fernández-de-Misa R
Int J Dermatol; 2014 Nov; 53(11):1417-22. PubMed ID: 24697305
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides.
de Coninck EC; Kim YH; Varghese A; Hoppe RT
J Clin Oncol; 2001 Feb; 19(3):779-84. PubMed ID: 11157031
[TBL] [Abstract][Full Text] [Related]
33. Mycosis fungoides. Topical use of nitrogen mustard in recurrent cases.
Arundell FD; Chan WH
Calif Med; 1968 Dec; 109(6):458-61. PubMed ID: 5724878
[TBL] [Abstract][Full Text] [Related]
34. Milia in regressing plaques of mycosis fungoides: provoked by topical nitrogen mustard or not?
Kalayciyan A; Oguz O; Demirkesen C; Serdaroglu S; Kotogyan A
Int J Dermatol; 2004 Dec; 43(12):953-6. PubMed ID: 15569030
[TBL] [Abstract][Full Text] [Related]
35. Focal contact sensitivity to nitrogen mustard in lesions of cutaneous T-cell lymphoma (mycosis fungoides).
Shelley WB
Acta Derm Venereol; 1981; 61(2):161-4. PubMed ID: 6165197
[TBL] [Abstract][Full Text] [Related]
36. Topical mechlorethamine in the treatment of mycosis fungoides. Uniformity of application and potential for environmental contamination.
Breneman DL; Nartker AL; Ballman EA; Pruemer JM; Blumsack RF; Davis M; Breneman JC
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 1):1059-64. PubMed ID: 1844356
[TBL] [Abstract][Full Text] [Related]
37. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
38. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
39. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
Liner K; Brown C; McGirt LY
Drug Des Devel Ther; 2018; 12():241-254. PubMed ID: 29440874
[TBL] [Abstract][Full Text] [Related]
40. Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy.
Hamminga B; Noordijk EM; van Vloten WA
Arch Dermatol; 1982 Mar; 118(3):150-3. PubMed ID: 7065660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
